{"title":"denosumab相关性甲状旁腺功能亢进1例:鉴别诊断的挑战","authors":"Taşkıran Emin, Şahin Sevnaz, Savaş Sumru, Saraç Zeliha Fulden, Akçiçek Selahattin Fehmi","doi":"10.17352/2455-8591.000033","DOIUrl":null,"url":null,"abstract":"Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge\",\"authors\":\"Taşkıran Emin, Şahin Sevnaz, Savaş Sumru, Saraç Zeliha Fulden, Akçiçek Selahattin Fehmi\",\"doi\":\"10.17352/2455-8591.000033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.\",\"PeriodicalId\":91288,\"journal\":{\"name\":\"International journal of immunotherapy and cancer research\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of immunotherapy and cancer research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17352/2455-8591.000033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of immunotherapy and cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/2455-8591.000033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge
Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
